ModifiedPremera BluecrossPolicy 5.01.662

Antiemetic Medications

Customize your policy alerts

Sign up for Premera Bluecross Policy 5.01.662 alerts

Get alerted when Policy 5.01.662 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Pharmacy benefit policy governing medical necessity criteria, quantity limits, and approval conditions for specific antiemetic drugs (including cancer-, pregnancy-, motion sickness-, and postoperative-related uses) for Premera Blue Cross members and prescribers.

Policy Summary

PayerPremera Bluecross

PolicyAntiemetic Medications

Policy CodePolicy 5.01.662

Change TypeConsolidation, additions, and quantity-limit updates

Effective DateAug 1, 2026

Last ReviewJul 27, 2026

Next Review DateJul 27, 2026

Key ActionObtain prior authorization through the pharmacy benefit and document prior OTC pyridoxine + doxylamine trial when requesting Bonjesta or Diclegis.

SourceLink

POLICY UPDATE CHANGES

Moved coverage criteria for multiple antiemetic drugs from policy 5.01.605 to policy 5.01.662 and added new/updated criteria and quantity limits for several agents.

Added new policy criteria for Nereus (tradipitant) for the treatment of vomiting induced by motion sickness.

Updated Bonjesta and Diclegis criteria to require prior trial and inadequate response or intolerance to OTC pyridoxine combined with OTC doxylamine.

Updated quantity limits: Akynzeo to 1 capsule per fill; Sancuso to 1 transdermal system per fill; Bonjesta limited to 60 tablets/30 days; Diclegis and generic delayed-release limited to 120 tablets/30 days; Varubi limited to 2 tablets per fill; Nereus quantity changed to 16 capsules/30 days.

Added brand dronabinol solution with the same criteria as Syndros (dronabinol oral solution).

1Akynzeo per fill

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

ModifiedPremera BluecrossPolicy 5.01.662

Antiemetic Medications

Customize your policy alerts

Sign up for Premera Bluecross Policy 5.01.662 alerts

Get alerted when Policy 5.01.662 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerPremera Bluecross

PolicyAntiemetic Medications

Policy CodePolicy 5.01.662

Change TypeConsolidation, additions, and quantity-limit updates

Effective DateAug 1, 2026

Last ReviewJul 27, 2026

Next Review DateJul 27, 2026

Key ActionObtain prior authorization through the pharmacy benefit and document prior OTC pyridoxine + doxylamine trial when requesting Bonjesta or Diclegis.

SourceLink

POLICY UPDATE CHANGES

Moved coverage criteria for multiple antiemetic drugs from policy 5.01.605 to policy 5.01.662 and added new/updated criteria and quantity limits for several agents.

Added new policy criteria for Nereus (tradipitant) for the treatment of vomiting induced by motion sickness.

Updated Bonjesta and Diclegis criteria to require prior trial and inadequate response or intolerance to OTC pyridoxine combined with OTC doxylamine.

Added brand dronabinol solution with the same criteria as Syndros (dronabinol oral solution).

1Akynzeo per fill

120/30dDiclegis / generic limit

NereusNew drug added

Coverage Criteria for Antiemetic Medications

Akynzeo (netupitant and palonosetron) — covered when ALL of the following are met

Covered when ALL of the following are met:

Akynzeo criteria: The individual is aged 18 years or older; has moderate-to-high emetic risk; medication is being used in combination with dexamethasone and a serotonin receptor antagonist (e.g., ondansetron); quantity limited to 1 capsule per fill.

oral use only

Emend (aprepitant) — oncologic — covered when ALL of the following are met (oncologic use)

Covered when ALL of the following are met (oncologic use):

Emend oncology criteria: The individual is aged 12 years or older; has moderate-to-high emetic risk; medication is being used in combination with dexamethasone and a serotonin receptor antagonist (e.g., ondansetron); has tried and had an inadequate response or intolerance to generic aprepitant; quantity limited to either two 80 mg capsules per fill or one TriPack per fill (one 125 mg + two 80 mg).

oral use only

Emend (aprepitant) — postoperative use

Covered when ALL of the following are met (postoperative use):

Emend postoperative criteria: The individual is aged 18 years or older; has tried and had an inadequate response or intolerance to generic aprepitant; quantity limited to either two 80 mg capsules per fill or one TriPack per fill (one 125 mg + two 80 mg).

oral use only

Sancuso (granisetron transdermal system) — oncologic

Covered when ALL of the following are met (oncologic use):

Sancuso pediatric criteria: The individual is aged 11 years or younger; has moderate-to-high emetic risk; medication is being used in combination with a serotonin receptor antagonist (e.g., ondansetron); quantity limits as specified elsewhere in policy.

transdermal system

Sancuso adult criteria: The individual is aged 18 years or older; has moderate-to-high emetic risk; medication is being used in combination with a serotonin receptor antagonist (e.g., ondansetron); quantity limits as specified elsewhere in policy.

transdermal system

Brand dronabinol solution / Syndros (dronabinol oral solution)

Covered when ALL of the following are met:

Dronabinol solution criteria: The individual is aged 18 years or older; requires treatment for either chemotherapy-associated nausea and vomiting after failing conventional antiemetic treatments or anorexia with weight loss in AIDS; has tried and had an inadequate response or intolerance to generic dronabinol capsules OR documentation that the solution is medically necessary (e.g., unable to swallow solids); quantity limits referenced elsewhere in policy.

oral solution

Varubi (rolapitant) — covered when ALL of the following are met

Covered when ALL of the following are met:

Varubi criteria: The individual is aged 18 years or older; has moderate-to-high emetic risk; medication is being used in combination with dexamethasone and a serotonin receptor antagonist (e.g., ondansetron); quantity limited to 2 tablets per fill.

solid dosage form

Nereus (tradipitant) — motion sickness related antiemetic

Covered when ALL of the following are met (motion‑sickness related use):

Nereus motion sickness criteria: The individual is 18 years or older; there is no evidence of another underlying condition causing chronic nausea; has tried and had an inadequate response or intolerance to two first-generation antihistamines (e.g., dimenhydrinate, diphenhydramine, meclizine) and to scopolamine patch; Nereus will not be used in combination with other anti‑nausea or anti‑emetic medications; dose limited to 170 mg daily; quantity limited to 16 capsules per 30 days; initial approval 30 days with each additional course evaluated as an initial authorization.170 mg daily

Initial approval 30 days; subsequent courses require re-evaluation

Doxylamine/pyridoxine products — pregnancy-related antiemetics (criteria)

Covered when ALL of the following are met (treatment of nausea and vomiting of pregnancy):

Bonjesta criteria: Has tried and had an inadequate response or intolerance to over‑the‑counter pyridoxine combined with over‑the‑counter doxylamine AND has tried and had an inadequate response or intolerance to generic doxylamine and pyridoxine delayed‑release; quantity limited to 60 tablets per 30 days.

extended‑release product

Diclegis criteria: Has tried and had an inadequate response or intolerance to over‑the‑counter pyridoxine combined with over‑the‑counter doxylamine AND has tried and had an inadequate response or intolerance to generic doxylamine and pyridoxine delayed‑release; quantity limited to 60 tablets per 30 days.

delayed‑release product

Generic doxylamine/pyridoxine criteria: Has tried and had an inadequate response or intolerance to over‑the‑counter pyridoxine combined with over‑the‑counter doxylamine; quantity limited to 120 tablets per 30 days.

generic delayed‑release

General coverage stance — specified antiemetic medications covered when drug-specific criteria and quantity limits are met

Policy‑level coverage stance: Covered when ALL of the following are met:

Policy-level requirements: Drugs listed have drug‑specific medical necessity criteria and quantity limits; prior OTC trial of pyridoxine plus doxylamine is required before coverage of Bonjesta or Diclegis.

See drug-specific sections for per‑drug limits and additional requirements.

All uses of the drugs described in this policy that are not specifically enumerated in the drug-specific medical necessity sections are investigational. Requests for coverage of indications or clinical scenarios not listed in the policy will be evaluated as investigational and are not considered medically necessary under this policy.

This medical policy does not apply to Medicare Advantage members. Member benefits for Medicare Advantage plans may differ; providers and members should consult the member benefit booklet or contact member services to determine applicable coverage for a specific service or drug.

Uses of the drugs that are not specified among the policy’s listed indications are considered investigational / not medically necessary. Coverage is limited to those indications and criteria explicitly described in the policy; therapies requested for other conditions or without the required supporting documentation should be treated as not medically necessary.

Coding

Codingmixed

No codes listed

Provider Actions, Prior Authorization, and Documentation

Prior Authorization

Pharmacy benefit — prior authorization required

This policy is managed through the pharmacy benefit; drugs listed in the policy require adherence to the medical necessity criteria and prior authorization as managed by the pharmacy benefit.

Prior Authorization

Prior authorization for listed prescription drugs

Prescription drugs listed have specific coverage criteria and quantity limits; prior authorization is required per pharmacy procedures when those criteria or limits apply.

Step Therapy

Step/tiered therapy — trial then failure/intolerance required

Several branded agents require documentation of a prior trial with inadequate response or intolerance to generic or OTC alternatives before approval.

Initial Therapy Criteria

Nereus initial therapy

Initial therapy:

Nereus initial approval: Initial approval will be for 30 days; subsequent treatment courses will be evaluated as an initial authorization and the individual must meet the medical necessity criteria as listed above.

Dose limit 170 mg daily; quantity limit 16 capsules per 30 days

Continuation / Re-authorization Criteria

Continuation therapy / re-authorization criteria

Re-authorization / continuation therapy:

Re-authorization criteria: Re-authorization of all drugs listed may be approved up to 12 months as long as drug‑specific coverage criteria are met and chart notes demonstrate continued positive clinical response to therapy.12 months

Unless noted otherwise for specific drugs

Step Therapy Requirements

Required element	Documentation to submit
Patient identifier and diagnosis (indication for therapy)
Age of the individual (when age-specific criteria apply)
Description of prior therapies tried and dates (including generic equivalents) and reason for failure or intolerance
For oncology antiemetics: documentation that medication is being used in combination with dexamethasone and a serotonin receptor antagonist (e.g., ondansetron)
For Bonjesta/Diclegis: documentation of trial and inadequate response or intolerance to over-the-counter pyridoxine combined with over-the-counter doxylamine
For branded dronabinol solution/Syndros: documentation of prior trial and inadequate response or intolerance to generic dronabinol capsules OR documentation of medical need for solution formulation (e.g., unable to swallow solids)
Requested quantity, dose, and frequency consistent with policy limits (e.g., Akynzeo: 1 capsule per fill; Varubi: 2 tablets per fill; Bonjesta: 60 tablets/30 days; Diclegis/generic DR: 120 tablets/30 days; Nereus: 16 capsules/30 days)
Clinical rationale for use when prior trials are documented as inadequate or not tolerated (clinical notes describing response/intolerance)
For Nereus (tradipitant): documentation that two first-generation antihistamines and scopolamine patch were tried and inadequate or not tolerated, absence of other causes of chronic nausea, and proposed dosing (dose limit 170 mg/day)

Step therapy requirement	Coverage label
Prior trial of over-the-counter pyridoxine in combination with over-the-counter doxylamine with documentation of inadequate response or intolerance
If OTC pyridoxine + OTC doxylamine trial documented and inadequate/intolerant, trial of generic doxylamine and pyridoxine delayed‑release with documentation of inadequate response or intolerance (Bonjesta/Diclegis specific)
Requests that do not document the required OTC trial(s) and subsequent failures/intolerances may be denied

Quantity Limits by Drug

Akynzeo (netupitant and palonosetron) — quantity limit

DrugAkynzeo (netupitant and palonosetron)

Quantity limit1 capsule per fill

Use restrictionOral use only; for prevention of chemotherapy-associated nausea and vomiting in adults with moderate-to-high emetic risk when used with dexamethasone and a 5-HT3 RA

Emend (aprepitant) — two 80 mg capsules or one TriPack (one 125 mg + two 80 mg)

DrugEmend (aprepitant)

Quantity options per fillTwo 80 mg capsules OR one TriPack (one 125 mg + two 80 mg)

Age & use

Background

Nausea and vomiting result from stimulation of the central vomiting center by multiple afferent pathways, including the chemoreceptor trigger zone, gastrointestinal tract, pharynx and higher cortical centers. Key neurotransmitter systems involved include serotonin (5-HT3) and dopamine, with contributions from acetylcholine, histamine, cannabinoid, opioid and neurokinin-1 (NK1) receptors. Selection of antiemetic therapy is guided by the emetic stimulus and the receptors involved (for example, chemotherapy-induced emesis often requires combination regimens that target multiple receptor pathways).

Definitions and Clinical Context

Emetic risk — chemotherapy-induced nausea and vomiting risk categories

DefinitionEmetic risk: risk of chemotherapy-induced nausea and vomiting categorized as moderate or high; used to determine when combination antiemetic regimens (including NK1 RAs) are indicated.

Clinical useEmetic risk guides selection of combination regimens (e.g., NK1 RA + 5-HT3 RA + dexamethasone)

Source guidanceAligned with NCCN recommendations for antiemesis

High-emetic-risk oncology antiemetic regimen — NCCN-recommended regimen description

Recommended regimen (high emetic risk)Olanzapine + NK1 RA + 5-HT3 RA + dexamethasone

Moderate risk options5-HT3 RA + dexamethasone; or olanzapine + palonosetron + dexamethasone; or NK1 RA + 5-HT3 RA + dexamethasone

Site of Care

Note

Pharmacy benefit / retail dispensing (site of care)

Managed under the pharmacy benefit; dispensing and retail pharmacy settings apply per pharmacy benefit rules (site of care = home/retail dispensing).

Policy Summary

PayerPremera Bluecross

PolicyAntiemetic Medications

Policy CodePolicy 5.01.662

Change TypeConsolidation, additions, and quantity-limit updates

Effective DateAug 1, 2026

Last ReviewJul 27, 2026

Next Review DateJul 27, 2026

Key ActionObtain prior authorization through the pharmacy benefit and document prior OTC pyridoxine + doxylamine trial when requesting Bonjesta or Diclegis.

SourceLink

On This Page

Examples include prior trial/inadequate response or intolerance to generic aprepitant before Emend, and to generic dronabinol capsules before brand dronabinol solution/Syndros.

Step Therapy

Step therapy — OTC pyridoxine + doxylamine required first

For Bonjesta, Diclegis, and generic doxylamine–pyridoxine delayed-release, the individual must have tried and had an inadequate response or intolerance to over-the-counter pyridoxine combined with over-the-counter doxylamine prior to coverage of the prescription products.

Bonjesta and Diclegis criteria explicitly require prior OTC pyridoxine + OTC doxylamine trial and inadequate response or intolerance.
Generic delayed‑release doxylamine/pyridoxine also requires prior OTC pyridoxine + OTC doxylamine trial.

Documentation Required

Required documentation — clinical records and prior trials

Submit medical records/chart notes that document the diagnosis, relevant history, physical evaluation, medication history, and information demonstrating that the medical necessity criteria are met when requesting prior authorization.

Include documentation of prior OTC trial of pyridoxine plus doxylamine when seeking coverage for Bonjesta or Diclegis.
Document prior therapy failures or intolerances when required by the drug-specific criteria.

Documentation Required

Document prior OTC pyridoxine + doxylamine trial (policy change)

Policy consolidation moved prior criteria from policy 5.01.605; providers must document the prior OTC trial of pyridoxine plus doxylamine when requesting coverage for Bonjesta or Diclegis.

Denial Risk

Denial risk — unmet criteria or missing documentation

Requests that do not meet the drug‑specific medical necessity criteria, lack required documentation (including prior OTC pyridoxine + doxylamine trial when applicable), or exceed specified quantity limits may be denied.

Failure to meet updated coverage criteria (including required prior OTC trial for doxylamine/pyridoxine products) or to adhere to specific quantity limits may trigger coverage denial.

Denial Risk

Denial triggers — failure to meet criteria or quantity limits

Coverage denials may be triggered by failure to meet updated coverage criteria (including required prior OTC trial for doxylamine/pyridoxine products) or by requests exceeding the policy's quantity limits.

Examples: not documenting prior OTC pyridoxine + doxylamine trial for Bonjesta/Diclegis; exceeding Bonjesta (60/30 days), Diclegis/generic DR (120/30 days), Akynzeo (1 per fill), Varubi (2 per fill), or Nereus (16/30 days) limits.

Oncologic: age 12 years or older; used with dexamethasone and a 5-HT3 RA

Varubi (rolapitant) — quantity limit 2

DrugVarubi (rolapitant)

Quantity limit2 tablets per fill

UsePrevention of chemotherapy-associated nausea and vomiting in adults when used with dexamethasone and a 5-HT3 RA

Bonjesta / Diclegis / generic doxylamine-pyridoxine — Bonjesta 60 tablets / Diclegis generic DR 120 tablets

ProductsBonjesta (doxylamine–pyridoxine ER) and Diclegis (doxylamine–pyridoxine DR)

Bonjesta limit60 tablets per 30 days

Diclegis/generic DR noteDiclegis listed with a 60-tablet limit in one section; generic delayed-release limited to 120 tablets per 30 days per policy history

Nereus (tradipitant) — quantity limit 16

DrugNereus (tradipitant)

Quantity limit16 capsules per 30 days

Dose & useDose limited to 170 mg daily; indicated for prevention of vomiting induced by motion sickness in adults

Akynzeo (netupitant and palonosetron) — quantity limit (repeat/confirm)

DrugAkynzeo (netupitant and palonosetron)

Quantity limit (confirmation)1 capsule per fill (policy history confirms updated quantity limit)

ContextApplied for prevention of chemotherapy-associated nausea/vomiting when used with dexamethasone and a 5-HT3 RA

Sancuso (granisetron transdermal system) — quantity limit 1

DrugSancuso (granisetron transdermal system)

Quantity limit1 transdermal system per fill

UsePrevention of chemotherapy-associated nausea and vomiting (adult and pediatric criteria described separately)

Bonjesta (doxylamine and pyridoxine ER) — quantity limit 60

DrugBonjesta (doxylamine and pyridoxine ER)

Quantity limit60 tablets per 30 days

RequirementPrior trial and inadequate response or intolerance to OTC pyridoxine + doxylamine and to generic DR formulation required

Diclegis (doxylamine and pyridoxine DR) and generic DR — quantity limit 120

ProductsDiclegis (doxylamine and pyridoxine delayed-release) and generic delayed-release

Quantity limitDiclegis: 60 tablets per 30 days (policy text); Generic DR: 120 tablets per 30 days (policy updates/history)

Prior stepRequires trial and inadequate response or intolerance to OTC pyridoxine + doxylamine before coverage

Varubi (rolapitant) — quantity limit 2 (repeat)

DrugVarubi (rolapitant)

Quantity limit (repeat)2 tablets per fill

IndicationPrevention of chemotherapy-associated nausea and vomiting in adults when used with dexamethasone and a 5-HT3 RA

Nereus (tradipitant) — quantity limit 16 (from separate chunk)

DrugNereus (tradipitant)

Quantity limit (separate note)16 capsules per 30 days (history notes change from prior 30 caps/15 days)

Approval durationInitial approval 30 days; each additional course evaluated as an initial authorization

Guideline sourceNCCN Clinical Practice Guidelines in Oncology: Antiemesis - Version 2.2025